Hospital costs, length of stay and mortality attributable to invasive scedosporiosis in haematology patients
Open Access
- 29 May 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (9) , 2274-2282
Abstract
Scedosporium species are increasingly recognized as a cause of invasive mould disease in haematology patients, but little is known about the hospitalization costs and outcomes attributable to invasive scedosporiosis (SCEDO). A retrospective case–control study was undertaken during 2002–10 to determine the attributable inpatient costs, length of stay (LOS) and mortality associated with SCEDO in haematology patients. Case patients with SCEDO (n = 30) were matched 1 : 2 to controls (n = 60) according to haematological diagnosis, admission year and age. Diagnostics, antifungal drugs, ward and other SCEDO-related costs were estimated using actual cost data. Median regression modelling was used to adjust for variables that were not accounted for in the matched-pairs analysis. The crude total median cost of treating SCEDO was AU$32 182 per patient versus AU$17 424 per control. In multivariable analysis, SCEDO was associated with median excess costs of AU$23 611 (95% CI = AU$17 992–AU$29 231; P < 0.001), approximating US$15 509 at purchasing power parity, with prolonged LOS of 13 days (95% CI = 8.2–17.8 days; P < 0.001). Exclusion of cases and matched pairs with early death further increased the median excess cost and LOS. The cost differential was driven by ward costs (64%, P = 0.005) and antifungal treatment costs (29%, P < 0.001). The all-cause inpatient mortality was 38 times higher for the SCEDO cases versus the control group (63.3% versus 1.7%; P < 0.001). SCEDO has substantial impact on hospital resource consumption, LOS and mortality in haematology patients. Risk factors and preventative measures for SCEDO should be further studied.Keywords
This publication has 28 references indexed in Scilit:
- Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United StatesMycoses, 2011
- Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infectionClinical Microbiology and Infection, 2009
- Outcome and Medical Costs of Patients with Invasive Aspergillosis and Acute Myelogenous Leukemia–Myelodysplastic Syndrome Treated with Intensive Chemotherapy: An Observational StudyClinical Infectious Diseases, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 PatientsAntimicrobial Agents and Chemotherapy, 2008
- Infection with Scedosporium apiospermum and S . prolificans , AustraliaEmerging Infectious Diseases, 2007
- Changing Epidemiology of Rare Mould InfectionsDrugs, 2007
- Infections Due to Scedosporium apiospermum and Scedosporium prolificans in Transplant Recipients: Clinical Characteristics and Impact of Antifungal Agent Therapy on OutcomeClinical Infectious Diseases, 2005
- Deep Infections Caused by Scedosporium prolificans: A Report on 16 Cases in Spain and a Review of the LiteratureMedicine, 1997
- Clinical Features of Human Infection with Scedosporium inflatumClinical Infectious Diseases, 1992